Detailed narrative
ASCENIV Performance and Market Penetration
ASCENIV demonstrated strong execution, with demand accelerating throughout Q2 FY26. June recorded the strongest sequential utilization growth since H1 2024, driven by increasing physician adoption, broader provider engagement, new patient starts, and higher patient utilization. Management believes current inventory levels are appropriate and consistent with underlying demand, reinforcing ASCENIV's early penetration in the later-line refractory primary immunodeficiency market.
BIVIGAM Stabilization Amidst Competitive Pressures
Despite competitive pressures in the U.S. immunoglobulin market, BIVIGAM demand stabilized during the quarter, showing sequential improvements in utilization and revenue. The company maintains a disciplined approach prioritizing profitable growth over unsustainable discounting. While BIVIGAM is expected to be down significantly year-over-year, its stabilization contributes to the overall product portfolio performance.
Real-World Evidence and Payer Access for ASCENIV
A significant development was the continued expansion of ASCENIV's real-world evidence base. An abstract submitted for the 2026 American College of Allergy, Asthma and Immunology Annual Scientific Meeting highlights statistically significant reductions in infection-related hospitalizations, outpatient healthcare utilization, and antibiotic/corticosteroid use in medically complex patients after ASCENIV initiation.
These findings are expected to further strengthen commercial payer access and physician adoption, complementing existing broad commercial payer coverage.
SG-001 Pipeline Advancement
ADMA is advancing SG-001 through a capital-efficient development pathway, with plasma collection optimization, potency assay development, and preclinical activities supporting planned cGMP conformance lot production in H2 2026. The company anticipates submitting its pre-IND meeting package to the FDA by year-end.
SG-001 is viewed as a potential solution for unmet medical needs in immunocompromised patients at high risk for severe pneumococcal disease, with a projected annual revenue opportunity of $300 million to $500 million if approved.
Financial Strength and Capital Allocation
The company ended the quarter with approximately $136 million in cash and cash equivalents and net leverage below 0.5 turn, with $100 million in additional borrowing capacity. This strong financial position provides flexibility for commercial expansion, manufacturing initiatives, and pipeline development.
ADMA repurchased 7.1 million shares during the quarter, bringing year-to-date repurchases to 13.8 million shares, representing 5.3% of outstanding common stock, and remains on track for its $200 million+ share repurchase target for 2026.
McKesson Partnership and Reimbursement Dynamics
The partnership with McKesson is seen as an important part of the go-forward strategy for ASCENIV penetration, particularly in GPO buying groups focused on secondary immune deficiency, which represents new call points. Payment terms with McKesson are noted as faster than other customers.
Commercial payer access for ASCENIV and BIVIGAM remains broad, with increased utilization through the commercial channel driven by real-world data. Prior authorization is common across the IG landscape, and ADMA's team is actively engaged with payers to secure improved access.